Company

Company profile: smart biotech for odor management

ChemCom is the leading discovery company for products and services related to chemical communications mediated by human olfactory and taste receptors. ChemCom offers a unique, patented technological platform based on an exclusive worldwide license acquired from Duke University. Its offices are located in Brussels on the Erasme Medical Campus (ULB) where it currently employs 13 people. The findings have been gathered in a database that enables the Company to reproduce an artificial nose that expresses the whole repertoire of human Olfactory Receptors (hORs). The applications of ChemCom’s research allow for the development of new products and technologies for consumer needs in the area of flavors & fragrances, but also all industries that deal with odor or taste issues. The applications of ChemCom’s research leads the development of new products and technologies for consumer needs in multiple areas. In the Flavor and Fragrance industry, the company’s main area of focus, ChemCom’s platform and product portfolios represent an innovative approach with successful solutions for:

              • Malodor counteraction

                        • Development of new fragrance materials

                                  • Creation of cost-effective formulations

                                Thanks to the therapeutic characteristics of GPCRs, ChemCom’s research can also be leveraged in pharmaceutical markets (Drug Discovery: oncology, immunology, etc).

                                image

                                History

                                Based on solid results, ChemCom has focused on the proof of concept of its technology.

                                • 1991

                                  First code on Olfactory Receptors (ORs) genes (Buck and Axel), showing that they belong to the family of G Protein-Coupled Receptors (GPCRs). They estimated that there were approximately one thousand different genes for ORs in the mammalian genome.

                                • 2000

                                  Foundation of ChemCom cc_newlogo_201609

                                • 2005

                                  Licensing-in of the chaperones technology from Duke University.

                                • 2007

                                  Partnership with Givaudan.

                                • 2012

                                  End of partnership with Givaudan.

                                • 2013

                                  Partnership with an international group for a research program broken down into several milestones.

                                • 2015

                                  Partnership with an international beverage group. Renewal of partnership following encouraging results on first milestone.

                                • 2016

                                  First pharmaceutical development. The BioWin project agreement focuses on oncology applications based on GPCRs.